Metoprolol Alvogen

Metoprolol succinate, the active ingredient in Metoprolol Alvogen, is a beta blocker presented as an oral tablet for oral use. It is employed to treat hypertension, angina pectoris, chronic heart failure, and to provide post‑myocardial infarction prophylaxis in adult patients.

GNH USA supplies Metoprolol Alvogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol Alvogen is a beta‑adrenergic blocker indicated for several cardiovascular conditions.

Hypertension: lowers systemic blood pressure and reduces cardiovascular risk. Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. Chronic heart failure: improves ventricular function and reduces hospitalisation. Post‑myocardial infarction prophylaxis: lowers the chance of recurrent cardiac events.

Metoprolol Alvogen may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Headache - Bradycardia (slow heart rate) - Cold extremities - Gastrointestinal upset (nausea, abdominal discomfort)

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in patients with asthma or COPD - Allergic reactions (rash, angioedema) - Depression or mood changes - Worsening heart failure

Before initiating therapy, clinicians should consider several safety aspects.

Monitor blood pressure: ensure adequate control without excessive drop. Assess heart rate: avoid use in patients with resting bradycardia. Use caution in asthma/COPD: β1‑selectivity may still affect bronchial tone. Adjust in renal/hepatic impairment: dose may need modification. Avoid abrupt discontinuation: taper to prevent rebound tachycardia. Store at room temperature: keep in the original pack, protect from moisture.

Metoprolol succinate can interact with a variety of medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Non‑selective beta blockers in severe asthma: risk of bronchospasm. - Other AV‑node blockers (verapamil, diltiazem): may cause profound bradycardia. - Clonidine withdrawal: can precipitate hypertension. - MAO inhibitors: may enhance hypotensive effect. - Potent CYP2D6 inhibitors (quinidine, paroxetine): increase metoprolol levels.

Moderate Interactions (Monitor Closely): - Diuretics: may amplify hypotensive response. - ACE inhibitors or ARBs: additive blood‑pressure lowering. - NSAIDs: may reduce antihypertensive effect. - Calcium‑channel blockers: monitor for bradycardia. - Antidiabetic agents: may mask hypoglycaemia symptoms.